Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.61 |
| ▸ | BRAF | P15056 | 11/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763857 | 0.91 | MAPK13 (0.61) | RAF1BRAFPIK3CAMAPTCYP1A2 | |
| SCHEMBL12764389 | 0.90 | NT5E (0.59) | BRAFMAPTNPC1RAB9AMAPK14 | |
| SCHEMBL1517272 | 0.88 | RAF1 (0.57) | RAF1BRAFPIK3CAMAPTMAPK13 | |
| SCHEMBL12764316 | 0.81 | MAPT (0.65) | MAPTNPC1RAB9AMAPK14ALDH1A1 | |
| SCHEMBL7692421 | 0.81 | MAPK13 (0.60) | RAF1BRAFPIK3CAMAPK13NPC1 | |
| SCHEMBL12764085 | 0.81 | MAPK14 (0.69) | RAF1BRAFMAPK13MAPK14 | |
| SCHEMBL12764344 | 0.81 | MEN1 (0.57) | RAF1CYP1A2CYP2C19MAPK14ALDH1A1 | |
| SCHEMBL4833700 | 0.80 | MAPK13 (0.61) | RAF1BRAFPIK3CAMAPK13NPC1 | |
| SCHEMBL12764356 | 0.80 | ALDH1A1 (0.57) | RAF1CYP1A2CYP2C19RAB9AMAPK14 | |
| SCHEMBL12764351 | 0.79 | MAPT (0.62) | MAPTNPC1RAB9AMAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906522-B2 | 2-aminoquinazoline derivatives | KYOWA HAKKO KIRIN CO., LTD (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | SLC7A1, SLC38A7, PRMT7 | RAF1 780/4885BRAF 1985/4885PIK3CD 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.